← Back to Search

Carbon-14-Labeled LY3556050 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to day 21 post dose
Awards & highlights

Study Summary

This trial tests how much of a drug passes from blood to urine, feces, air in healthy males. It also measures how much gets into the bloodstream and how long it takes to be removed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to day 21 post dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to day 21 post dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fecal Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Secondary outcome measures
PK: AUC (0-∞) of Total Radioactivity in Plasma and Blood
PK: AUC(0-tlast) of Total Radioactivity in Plasma and Blood
PK: Area Under the Curve Concentration Versus Time Curve From zero to Infinity (AUC [0-∞]) of LY3556050 in Plasma
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: [14C]-LY3556050Experimental Treatment1 Intervention
Single dose of [¹⁴C]-LY3556050 administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[14C]-LY3556050
2023
Completed Phase 1
~10

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,613 Previous Clinical Trials
3,200,922 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,344 Previous Clinical Trials
405,245 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment criteria in this clinical trial limited to those above 50 years of age?

"According to the requirements, participants must be within the age bracket of 18-55. There are 63 trials for those younger than 18 and 405 studies that involve patients aged 65 or older."

Answered by AI

To whom does this trial offer participation?

"For inclusion in this research, participants must be healthy adults aged between 18 and 55. A total of 7 individuals are eligible to partake in the study."

Answered by AI

Are any additional participants being sought for this clinical experiment?

"Clinicaltrials.gov indicates that this medical study is no longer enrolling patients; it first appeared on September 20th, 2023 and was last updated on the 18th of September. Nonetheless, 834 other trials are still open to candidates at present."

Answered by AI

Has [14C]-LY3556050 received a clearance from the FDA?

"Due to the early stage of testing, our team at Power has assigned [14C]-LY3556050 a safety score of 1. Phase 1 clinical trials provide limited evidence for both efficacy and security."

Answered by AI

What is the overall aim of this experiment?

"As per the trial sponsor Eli Lilly and Company, the primary endpoint of this investigation is to measure Fecal Excretion of LY3556050 Radioactivity over a specific period. Additionally, further outcomes that will be evaluated are PK: AUC(0-tlast) (Area Under the Curve Concentration Versus Time Curve From zero to Last Measurement Point] of Total Radioactivity in Plasma and Blood; PK: Area Under the curve from Zero To Infinity (AUC [0-∞]) for Ly 3556050 In Plasma; AndPK: AUC (0-∞) Of Total Radioactivity in Plasma and"

Answered by AI

Who else is applying?

What site did they apply to?
LabCorp CRU, Inc.
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants
2023. "A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06052462.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top